Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 83
Filter
Add more filters

Publication year range
1.
Nat Immunol ; 22(7): 839-850, 2021 07.
Article in English | MEDLINE | ID: mdl-34168371

ABSTRACT

Granulomas are complex cellular structures composed predominantly of macrophages and lymphocytes that function to contain and kill invading pathogens. Here, we investigated the single-cell phenotypes associated with antimicrobial responses in human leprosy granulomas by applying single-cell and spatial sequencing to leprosy biopsy specimens. We focused on reversal reactions (RRs), a dynamic process whereby some patients with disseminated lepromatous leprosy (L-lep) transition toward self-limiting tuberculoid leprosy (T-lep), mounting effective antimicrobial responses. We identified a set of genes encoding proteins involved in antimicrobial responses that are differentially expressed in RR versus L-lep lesions and regulated by interferon-γ and interleukin-1ß. By integrating the spatial coordinates of the key cell types and antimicrobial gene expression in RR and T-lep lesions, we constructed a map revealing the organized architecture of granulomas depicting compositional and functional layers by which macrophages, T cells, keratinocytes and fibroblasts can each contribute to the antimicrobial response.


Subject(s)
Leprosy, Lepromatous/immunology , Leprosy, Tuberculoid/immunology , Mycobacterium leprae/immunology , Skin/immunology , Adolescent , Adult , Aged , Female , Fibroblasts/immunology , Fibroblasts/microbiology , Fibroblasts/pathology , Gene Expression Profiling , Host-Pathogen Interactions , Humans , Keratinocytes/immunology , Keratinocytes/microbiology , Keratinocytes/pathology , Leprosy, Lepromatous/genetics , Leprosy, Lepromatous/microbiology , Leprosy, Lepromatous/pathology , Leprosy, Tuberculoid/genetics , Leprosy, Tuberculoid/microbiology , Leprosy, Tuberculoid/pathology , Macrophages/immunology , Macrophages/microbiology , Macrophages/pathology , Male , Middle Aged , Mycobacterium leprae/pathogenicity , RNA-Seq , Single-Cell Analysis , Skin/microbiology , Skin/pathology , T-Lymphocytes/immunology , T-Lymphocytes/microbiology , T-Lymphocytes/pathology , Transcriptome
2.
Cell ; 170(5): 973-985.e10, 2017 Aug 24.
Article in English | MEDLINE | ID: mdl-28841420

ABSTRACT

Mycobacterium leprae causes leprosy and is unique among mycobacterial diseases in producing peripheral neuropathy. This debilitating morbidity is attributed to axon demyelination resulting from direct interaction of the M. leprae-specific phenolic glycolipid 1 (PGL-1) with myelinating glia and their subsequent infection. Here, we use transparent zebrafish larvae to visualize the earliest events of M. leprae-induced nerve damage. We find that demyelination and axonal damage are not directly initiated by M. leprae but by infected macrophages that patrol axons; demyelination occurs in areas of intimate contact. PGL-1 confers this neurotoxic response on macrophages: macrophages infected with M. marinum-expressing PGL-1 also damage axons. PGL-1 induces nitric oxide synthase in infected macrophages, and the resultant increase in reactive nitrogen species damages axons by injuring their mitochondria and inducing demyelination. Our findings implicate the response of innate macrophages to M. leprae PGL-1 in initiating nerve damage in leprosy.


Subject(s)
Antigens, Bacterial/metabolism , Disease Models, Animal , Glycolipids/metabolism , Leprosy/microbiology , Leprosy/pathology , Macrophages/immunology , Mycobacterium leprae/physiology , Animals , Axons/metabolism , Axons/pathology , Demyelinating Diseases , Larva/growth & development , Leprosy/immunology , Mycobacterium marinum/metabolism , Myelin Sheath/chemistry , Myelin Sheath/metabolism , Myelin Sheath/ultrastructure , Neuroglia/metabolism , Neuroglia/pathology , Nitric Oxide/metabolism , Zebrafish
3.
N Engl J Med ; 390(6): 580, 2024 Feb 08.
Article in English | MEDLINE | ID: mdl-38324505
4.
N Engl J Med ; 389(22): 2026-2027, 2023 Nov 30.
Article in English | MEDLINE | ID: mdl-38009621
5.
J Immunol ; 203(4): 911-921, 2019 08 15.
Article in English | MEDLINE | ID: mdl-31235553

ABSTRACT

Th17 cells play a critical role in the adaptive immune response against extracellular bacteria, and the possible mechanisms by which they can protect against infection are of particular interest. In this study, we describe, to our knowledge, a novel IL-1ß dependent pathway for secretion of the antimicrobial peptide IL-26 from human Th17 cells that is independent of and more rapid than classical TCR activation. We find that IL-26 is secreted 3 hours after treating PBMCs with Mycobacterium leprae as compared with 48 hours for IFN-γ and IL-17A. IL-1ß was required for microbial ligand induction of IL-26 and was sufficient to stimulate IL-26 release from Th17 cells. Only IL-1RI+ Th17 cells responded to IL-1ß, inducing an NF-κB-regulated transcriptome. Finally, supernatants from IL-1ß-treated memory T cells killed Escherichia coli in an IL-26-dependent manner. These results identify a mechanism by which human IL-1RI+ "antimicrobial Th17 cells" can be rapidly activated by IL-1ß as part of the innate immune response to produce IL-26 to kill extracellular bacteria.


Subject(s)
Immunity, Innate/immunology , Interleukin-1beta/immunology , Interleukins/immunology , Lymphocyte Activation/immunology , Th17 Cells/immunology , Bacterial Infections/immunology , Humans , Interleukin-1beta/metabolism , Interleukins/metabolism , Th17 Cells/microbiology
8.
J Immunol ; 200(9): 3244-3258, 2018 05 01.
Article in English | MEDLINE | ID: mdl-29610140

ABSTRACT

Upon recognition of a microbial pathogen, the innate and adaptive immune systems are linked to generate a cell-mediated immune response against the foreign invader. The culture filtrate of Mycobacterium tuberculosis contains ligands, such as M. tuberculosis tRNA, that activate the innate immune response and secreted Ags recognized by T cells to drive adaptive immune responses. In this study, bioinformatics analysis of gene-expression profiles derived from human PBMCs treated with distinct microbial ligands identified a mycobacterial tRNA-induced innate immune network resulting in the robust production of IL-12p70, a cytokine required to instruct an adaptive Th1 response for host defense against intracellular bacteria. As validated by functional studies, this pathway contained a feed-forward loop, whereby the early production of IL-18, type I IFNs, and IL-12p70 primed NK cells to respond to IL-18 and produce IFN-γ, enhancing further production of IL-12p70. Mechanistically, tRNA activates TLR3 and TLR8, and this synergistic induction of IL-12p70 was recapitulated by the addition of a specific TLR8 agonist with a TLR3 ligand to PBMCs. These data indicate that M. tuberculosis tRNA activates a gene network involving the integration of multiple innate signals, including types I and II IFNs, as well as distinct cell types to induce IL-12p70.


Subject(s)
Interleukin-12/immunology , Mycobacterium tuberculosis/immunology , RNA, Bacterial/immunology , RNA, Transfer/immunology , Tuberculosis/immunology , Cell Differentiation/immunology , Gene Regulatory Networks/immunology , Humans , Immunity, Cellular/immunology , Immunity, Innate/immunology , Interleukin-12/biosynthesis , Lymphocyte Activation/immunology , Receptors, Pattern Recognition/immunology , Th1 Cells/immunology
9.
Proc Natl Acad Sci U S A ; 114(27): 7101-7105, 2017 07 03.
Article in English | MEDLINE | ID: mdl-28634290

ABSTRACT

Because of increased numbers of recorded pertussis cases in the United States, this study sought to understand the role of nonmedical vaccine exemptions and waning immunity may have had on the resurgence of pertussis in the United States at the community level. We used geospatial scan statistics, SaTScan, version 9.4, to analyze nonmedical vaccine exemptions of children entering kindergarten in 2011 and 2012 and reported pertussis cases in 2012 for children in age groups 5 years and younger and 10 to 14 years. Eight statistically significant clusters of nonmedical vaccine exemptions in kindergarteners and 11 statistically significant clusters of pertussis cases in children and adolescents were identified and geospatially linked. Forty-five percent of the counties in the study had high rates of nonmedical vaccine exemptions. The proportion of kindergarteners with nonmedical vaccine exemptions was 2.8 times larger in the identified exemption clusters. In addition, 31 counties had geographic clusters of high rates of pertussis in children ages 10 to 14 years old, consistent with waning immunity. Our findings are consistent with the view that geographic clusters of nonmedical vaccine exemptions and waning immunity may have been factors contributing to community-level pertussis outbreaks.


Subject(s)
Disease Outbreaks , Pertussis Vaccine/therapeutic use , Vaccination Refusal , Whooping Cough/diagnosis , Whooping Cough/epidemiology , Adolescent , Child , Child, Preschool , Cluster Analysis , Geography , Humans , Immunization Programs , Infant , Infant, Newborn , United States , Vaccination/statistics & numerical data
10.
Lancet ; 391(10125): 1108-1120, 2018 03 17.
Article in English | MEDLINE | ID: mdl-29179954

ABSTRACT

The World Bank is publishing nine volumes of Disease Control Priorities, 3rd edition (DCP3) between 2015 and 2018. Volume 9, Improving Health and Reducing Poverty, summarises the main messages from all the volumes and contains cross-cutting analyses. This Review draws on all nine volumes to convey conclusions. The analysis in DCP3 is built around 21 essential packages that were developed in the nine volumes. Each essential package addresses the concerns of a major professional community (eg, child health or surgery) and contains a mix of intersectoral policies and health-sector interventions. 71 intersectoral prevention policies were identified in total, 29 of which are priorities for early introduction. Interventions within the health sector were grouped onto five platforms (population based, community level, health centre, first-level hospital, and referral hospital). DCP3 defines a model concept of essential universal health coverage (EUHC) with 218 interventions that provides a starting point for country-specific analysis of priorities. Assuming steady-state implementation by 2030, EUHC in lower-middle-income countries would reduce premature deaths by an estimated 4·2 million per year. Estimated total costs prove substantial: about 9·1% of (current) gross national income (GNI) in low-income countries and 5·2% of GNI in lower-middle-income countries. Financing provision of continuing intervention against chronic conditions accounts for about half of estimated incremental costs. For lower-middle-income countries, the mortality reduction from implementing the EUHC can only reach about half the mortality reduction in non-communicable diseases called for by the Sustainable Development Goals. Full achievement will require increased investment or sustained intersectoral action, and actions by finance ministries to tax smoking and polluting emissions and to reduce or eliminate (often large) subsidies on fossil fuels appear of central importance. DCP3 is intended to be a model starting point for analyses at the country level, but country-specific cost structures, epidemiological needs, and national priorities will generally lead to definitions of EUHC that differ from country to country and from the model in this Review. DCP3 is particularly relevant as achievement of EUHC relies increasingly on greater domestic finance, with global developmental assistance in health focusing more on global public goods. In addition to assessing effects on mortality, DCP3 looked at outcomes of EUHC not encompassed by the disability-adjusted life-year metric and related cost-effectiveness analyses. The other objectives included financial protection (potentially better provided upstream by keeping people out of the hospital rather than downstream by paying their hospital bills for them), stillbirths averted, palliative care, contraception, and child physical and intellectual growth. The first 1000 days after conception are highly important for child development, but the next 7000 days are likewise important and often neglected.


Subject(s)
Delivery of Health Care/organization & administration , Global Health , Health Priorities , Universal Health Insurance , Humans
12.
J Health Commun ; 24(5): 581-583, 2019.
Article in English | MEDLINE | ID: mdl-31262227

ABSTRACT

Immunization represents one of the greatest public health achievements. Vaccines save lives, make communities more productive and strengthen health systems. They are critical to attaining the UN Sustainable Development Goals. Vaccination also represents value for investment in public health. It is undisputedly one of the most cost-effective ways of avoiding disease, each year preventing 2-3 million deaths globally. We the concerned scientists, public health professionals, physicians, and child health advocates issue this Salzburg Statement along with the International Working Group on Vaccination and Public Health Solutions, proclaiming our unwavering commitment to universal childhood vaccination, and our pledge to support the development, testing, implementation, and evaluation of new, effective, and fact-based communication programs. Our goal is to explain vaccinations to parents or caregivers, answer their questions, address their concerns, and maintain public confidence in the personal, family and community protection that childhood vaccines provide. Every effort will also be made to communicate the dangers associated with these childhood illnesses to parents and communities since this information seems to have been lost in the present-day narrative. While vaccine misinformation has led to serious declines in community vaccination rates that require immediate attention, in other communities, particularly in low-income countries, issues such as lack of access. and unstable supply of vaccines need to be addressed.


Subject(s)
Patient Acceptance of Health Care , Vaccination/psychology , Vaccines/administration & dosage , Caregivers/education , Caregivers/psychology , Child , Communication , Humans , Parents/education , Parents/psychology
16.
Am J Respir Crit Care Med ; 196(5): 628-637, 2017 09 01.
Article in English | MEDLINE | ID: mdl-28692301

ABSTRACT

RATIONALE: Existing trials of adjunctive vitamin D in the treatment of pulmonary tuberculosis (PTB) are variously limited by small sample sizes, inadequate dosing regimens, and high baseline vitamin D status among participants. Comprehensive analyses of the effects of genetic variation in the vitamin D pathway on response to vitamin D supplementation are lacking. OBJECTIVES: To determine the effect of high-dose vitamin D3 on response to antimicrobial therapy for PTB and to evaluate the influence of single-nucleotide polymorphisms (SNPs) in vitamin D pathway genes on response to adjunctive vitamin D3. METHODS: We conducted a clinical trial in 390 adults with PTB in Ulaanbaatar, Mongolia, who were randomized to receive four biweekly doses of 3.5 mg (140,000 IU) vitamin D3 (n = 190) or placebo (n = 200) during intensive-phase antituberculosis treatment. MEASUREMENTS AND MAIN RESULTS: The intervention elevated 8-week serum 25-hydroxyvitamin D concentrations (154.5 nmol/L vs. 15.2 nmol/L in active vs. placebo arms, respectively; 95% confidence interval for difference, 125.9-154.7 nmol/L; P < 0.001) but did not influence time to sputum culture conversion overall (adjusted hazard ratio, 1.09; 95% confidence interval, 0.86-1.36; P = 0.48). Adjunctive vitamin D3 accelerated sputum culture conversion in patients with one or more minor alleles for SNPs in genes encoding the vitamin D receptor (rs4334089, rs11568820) and 25-hydroxyvitamin D 1α-hydroxylase (CYP27B1: rs4646536) (adjusted hazard ratio ≥ 1.47; P for interaction ≤ 0.02). CONCLUSIONS: Vitamin D3 did not influence time to sputum culture conversion in the study population overall. Effects of the intervention were modified by SNPs in VDR and CYP27B1. Clinical trial registered with www.clinicaltrials.gov (NCT01657656).


Subject(s)
Antitubercular Agents/therapeutic use , Cholecalciferol/therapeutic use , Tuberculosis, Pulmonary/drug therapy , Vitamins/therapeutic use , Adult , Cholecalciferol/metabolism , Dietary Supplements , Dose-Response Relationship, Drug , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Mongolia , Polymorphism, Single Nucleotide/drug effects , Sputum/drug effects , Sputum/metabolism , Treatment Outcome , Vitamin D/analogs & derivatives , Vitamin D/metabolism , Vitamins/metabolism , Young Adult
18.
Am J Respir Crit Care Med ; 194(3): 345-55, 2016 08 01.
Article in English | MEDLINE | ID: mdl-26882070

ABSTRACT

RATIONALE: The development of host-targeted, prophylactic, and therapeutic interventions against tuberculosis requires a better understanding of the immune mechanisms that determine the outcome of infection with Mycobacterium tuberculosis. OBJECTIVES: To identify T-cell-dependent mechanisms that are protective in tuberculosis. METHODS: Multicolor flow cytometry, cell sorting and growth inhibition assays were employed to compare the frequency, phenotype and function of T lymphocytes from bronchoalveolar lavage or the peripheral blood. MEASUREMENTS AND MAIN RESULTS: At two independent study sites, bronchoalveolar lavage cells from donors with latent tuberculosis infection limited the growth of virulent Mycobacterium tuberculosis more efficiently than those in patients who developed disease. Unconventional, glycolipid-responsive T cells contributed to reduced mycobacterial growth because antibodies to CD1b inhibited this effect by 55%. Lipoarabinomannan was the most potent mycobacterial lipid antigen (activation of 1.3% T lymphocytes) and activated CD1b-restricted T cells that limited bacterial growth. A subset of IFN-γ-producing lipoarabinomannan-responsive T cells coexpressed the cytotoxic molecules perforin, granulysin, and granzyme B, which we termed polycytotoxic T cells. Taking advantage of two well-defined cohorts of subjects latently infected with Mycobacterium tuberculosis or patients who developed active disease after infection, we found a correlation between the frequency of polycytotoxic T cells and the ability to control infection (latent tuberculosis infection, 62%; posttuberculosis patients, 26%). CONCLUSIONS: Our data define an unconventional CD8(+) T-cell subset (polycytotoxic T cells) that is based on antigen recognition and function. The results link clinical and mechanistic evidence that glycolipid-responsive, polycytotoxic T cells contribute to protection against tuberculosis.


Subject(s)
Lipopolysaccharides/immunology , Mycobacterium tuberculosis/immunology , T-Lymphocyte Subsets/immunology , Tuberculosis/immunology , Flow Cytometry , Humans , Tuberculosis/prevention & control
19.
N Engl J Med ; 379(17): 1672-1674, 2018 10 25.
Article in English | MEDLINE | ID: mdl-30252629
20.
N Engl J Med ; 378(3): 291-293, 2018 01 18.
Article in English | MEDLINE | ID: mdl-29342389
SELECTION OF CITATIONS
SEARCH DETAIL